Differential contribution of inhibitory phosphorylation of CDC2 and CDK2 for unperturbed cell cycle control and DNA integrity checkpoints.
Inhibition of cyclin-dependent kinases (CDKs) by Thr14/Tyr15 phosphorylation is critical for normal cell cycle progression and is a converging event for several cell cycle checkpoints. In this study, we compared the relative contribution of inhibitory phosphorylation for cyclin A/B1-CDC2 and cyclin A/E-CDK2 complexes. We found that inhibitory phosphorylation plays a major role in the regulation of CDC2 but only a minor role for CDK2 during the unperturbed cell cycle of HeLa cells. The relative importance of inhibitory phosphorylation of CDC2 and CDK2 may reflect their distinct cellular functions. Despite this, expression of nonphosphorylation mutants of both CDC2 and CDK2 triggered unscheduled histone H3 phosphorylation early in the cell cycle and was cytotoxic. DNA damage by a radiomimetic drug or replication block by hydroxyurea stimulated a buildup of cyclin B1 but was accompanied by an increase of inhibitory phosphorylation of CDC2. After DNA damage and replication block, all cyclin-CDK pairs that control S phase and mitosis were to different degrees inhibited by phosphorylation. Ectopic expression of nonphosphorylated CDC2 stimulated DNA replication, histone H3 phosphorylation, and cell division even after DNA damage. Similarly, a nonphosphorylation mutant of CDK2, but not CDK4, disrupted the G2 DNA damage checkpoint. Finally, CDC25A, CDC25B, a dominant-negative CHK1, but not CDC25C or a dominant-negative WEE1, stimulated histone H3 phosphorylation after DNA damage. These data suggest differential contributions for the various regulators of Thr14/Tyr15 phosphorylation in normal cell cycle and during the DNA damage checkpoint.
Chow
Jeremy P H
JP
Department of Biochemistry, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong.
Siu
Wai Yi
WY
Ho
Horace T B
HT
Ma
Ken Hoi Tang
KH
Ho
Chui Chui
CC
Poon
Randy Y C
RY
D001973:Bromodeoxyuridine / Q000494:pharmacology; D016203:CDC2 Protein Kinase / Q000378:metabolism*; D042846:CDC2-CDC28 Kinases / Q000378:metabolism*; D002453:Cell Cycle; D018797:Cell Cycle Proteins; D004396:Coloring Agents / Q000494:pharmacology; D051357:Cyclin-Dependent Kinase 2; D004247:DNA / Q000737:chemistry / Q000378:metabolism; D004249:DNA Damage; D005434:Flow Cytometry; D005799:Genes, Dominant; D006367:HeLa Cells; D006657:Histones / Q000378:metabolism; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D008938:Mitosis; D009154:Mutation; D009687:Nuclear Proteins; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors
D018797:Cell Cycle Proteins; D004396:Coloring Agents; D006657:Histones; D009687:Nuclear Proteins; D004247:DNA; D011505:Protein-Tyrosine Kinases; C499349:WEE1 protein, human; D016203:CDC2 Protein Kinase; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2; D001973:Bromodeoxyuridine; D013936:Thymidine; D006918:Hydroxyurea